Top Markets
Coin of the day
Capha Pharmaceuticals Inc. Capha Pharmaceuticals Inc.

Capha Pharmaceuticals Inc.

FPSUF
Rank in Stocks #41990
Capha Pharmaceuticals Inc. currently conducts very limited business operations.... Capha Pharmaceuticals Inc. currently conducts very limited business operations. Its strategic aim is to delve into and pursue opportunities within the pharmaceutical distribution industry. The company, which was founded in 2004, previously operated as FPS Pharma Inc. until it adopted its present name, Capha Pharmaceuticals Inc., in January 2017. It is headquartered in West Kelowna, Canada.
Share Price
$0.0001
Last synced: 2025-12-05
Market Cap
$6.44K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
CA
Trade Capha Pharmaceuticals Inc. (FPSUF)

Category

P/E ratio for Capha Pharmaceuticals Inc. (FPSUF)
P/E ratio as of 2026 TTM: 0
According to Capha Pharmaceuticals Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Capha Pharmaceuticals Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.